Immuron ceo, steven lydeamore to present at ausbioinvest

Melbourne, australia, oct. 26, 2022 (globe newswire) -- immuron limited (asx: imc; nasdaq: imrn), an australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases; is pleased to provide investors with a copy of the presentation slide deck to be showcased at ausbioinvest 2022 in perth, australia on october 27, 2022, by our chief executive officer, steven lydeamore.
IMRN Ratings Summary
IMRN Quant Ranking